One of Innovative Medicines Canada’s guiding principles is to offer solutions that address challenges in the Canadian health system; access to new medicines is one such challenge.
We believe that information-sharing is essential to collaboratively finding solutions and ensuring the sustainability of Canadian health systems.
Toward this effort, Innovative Medicines Canada (IMC) has put together a pCPA Trends Update page to provide drug reimbursement updates and trends in Canada and OECD countries.
These resources are prepared and updated by IMC using aggregated and independently collected data. Sources include data from IQVIA International Reimbursement Comparison, Health Canada, Canadian Agency for Drugs and Technologies in Health (CADTH), Institut national d’excellence en santé et services sociaux (INESSS), pan-Canadian Pharmaceutical Alliance (pCPA), and various Canadian provincial formularies.
Trends related to time to access, volume of negations, and pCPA performance metrics are identified.
Source: IMC analysis of IQVIA International Reimbursement Comparison data. Arithmetic average of days from market authorization in each country to reimbursement in the same country. 632 days for Canada represents the best-case scenario (ie. Time from Health Canada approval to first provincial listing date).
Source: IMC analysis of IQVIA International Reimbursement Comparison data.
Source: IMC analysis of IQVIA International Reimbursement Comparison data and IQVIA Public Reimbursement data. CADTH and provincial listing timelines are for drugs with a pCPA LOI in the respective year. Provincial Listing is the average time from pCPA completed negotiation to provincial listing dates for drugs with a pCPA LOI. CADTH, pCPA, and provincial listing timelines are arithmetic averages.
Does not include drugs where negotiations were not pursued or subsequent pCPA attempts after the first attempt.
Source: IMC analysis of pCPA data collected from https://www.pcpacanada.ca/negotiations and CADTH data collected from https://cadth.ca/reimbursement-review-reports.
Source: IMC analysis of pCPA data collected from https://www.pcpacanada.ca/negotiations.
Source: IMC analysis of pCPA data collected from https://www.pcpacanada.ca/negotiations. pCPA files with a CADTH Project Number entry of « Not Applicable » were not included when estimating time to pCPA engagement, but were included when estimating duration of pCPA negotiations. % negotiations on BPG target includes files where both time to LOE and time to LOI could be estimated. Includes only pCPA files negotiated with a LOI.